These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 34416053)

  • 1. 'COVID vaccine arm' may present after both mRNA vaccines vaccination.
    Gregoriou S; Kleidona IA; Tsimpidakis A; Nicolaidou E; Stratigos A; Rigopoulos D
    J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):e867-e868. PubMed ID: 34416053
    [No Abstract]   [Full Text] [Related]  

  • 2. Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers. 'COVID-arm': a clinical and histological characterization.
    Fernandez-Nieto D; Hammerle J; Fernandez-Escribano M; Moreno-Del Real CM; Garcia-Abellas P; Carretero-Barrio I; Solano-Solares E; de-la-Hoz-Caballer B; Jimenez-Cauhe J; Ortega-Quijano D; Fernandez-Guarino M
    J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):e425-e427. PubMed ID: 33783873
    [No Abstract]   [Full Text] [Related]  

  • 3. [A red and swollen arm after vaccination for covid-19].
    De Mik D; Schot LJ; Privé B
    Ned Tijdschr Geneeskd; 2021 Nov; 165():. PubMed ID: 34854640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High anaphylaxis rates following vaccination with the Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers: a secondary analysis of initial post-approval safety data.
    Hashimoto T; Ozaki A; Bhandari D; Sawano T; Sah R; Tanimoto T
    J Travel Med; 2021 Oct; 28(7):. PubMed ID: 34128049
    [No Abstract]   [Full Text] [Related]  

  • 5. Positive aspects of the mRNA platform for SARS-CoV-2 vaccines.
    Hajissa K; Mussa A
    Hum Vaccin Immunother; 2021 Aug; 17(8):2445-2447. PubMed ID: 33830862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID Arm: Delayed Hypersensitivity Reactions to SARS-CoV-2 Vaccines Misdiagnosed as Cellulitis.
    Lindgren AL; Austin AH; Welsh KM
    J Prim Care Community Health; 2021; 12():21501327211024431. PubMed ID: 34120504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'COVID arm' - histological features of a delayed-type hypersensitivity reaction to Moderna mRNA-1273 SARS-CoV2 vaccine.
    Kempf W; Kettelhack N; Kind F; Courvoisier S; Galambos J; Pfaltz K
    J Eur Acad Dermatol Venereol; 2021 Nov; 35(11):e730-e732. PubMed ID: 34242422
    [No Abstract]   [Full Text] [Related]  

  • 8. A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®.
    Speich B; Chammartin F; Smith D; Stoeckle MP; Amico P; Eichenberger AL; Hasse B; Schuurmans MM; Müller T; Tamm M; Dickenmann M; Abela IA; Trkola A; Hirsch HH; Manuel O; Cavassini M; Hemkens LG; Briel M; Mueller NJ; Rauch A; Günthard HF; Koller MT; Bucher HC; Kusejko K;
    Trials; 2021 Oct; 22(1):724. PubMed ID: 34674742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Waning humoral response 6 months after SARS-CoV-2 vaccination with the mRNA-BNT162b2 vaccine in hemodialysis patients: time for a boost.
    Davidovic T; Schimpf J; Abbassi-Nik A; Stockinger R; Sprenger-Mähr H; Lhotta K; Zitt E
    Kidney Int; 2021 Dec; 100(6):1334-1335. PubMed ID: 34656642
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety Surveillance of COVID-19 mRNA Vaccines Through the Vaccine Safety Datalink.
    Blumenthal KG; Phadke NA; Bates DW
    JAMA; 2021 Oct; 326(14):1375-1377. PubMed ID: 34477809
    [No Abstract]   [Full Text] [Related]  

  • 11. Temporal Associations Between Immunization With the COVID-19 mRNA Vaccines and Myocarditis: The Vaccine Safety Surveillance System Is Working.
    Navar AM; McNally E; Yancy CW; O'Gara PT; Bonow RO
    JAMA Cardiol; 2021 Oct; 6(10):1117-1118. PubMed ID: 34185044
    [No Abstract]   [Full Text] [Related]  

  • 12. Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS).
    Welsh KJ; Baumblatt J; Chege W; Goud R; Nair N
    Vaccine; 2021 Jun; 39(25):3329-3332. PubMed ID: 34006408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.
    Roest S; Hoek RAS; Manintveld OC
    N Engl J Med; 2021 May; 384(20):1968-1970. PubMed ID: 33882226
    [No Abstract]   [Full Text] [Related]  

  • 14. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. Reply.
    Barda N; Dagan N; Balicer RD
    N Engl J Med; 2021 May; 384(20):1970. PubMed ID: 33882227
    [No Abstract]   [Full Text] [Related]  

  • 15. "COVID Arm": Very delayed large injection site reactions to mRNA COVID-19 vaccines.
    Ramos CL; Kelso JM
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2480-2481. PubMed ID: 33864927
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel.
    Swift MD; Breeher LE; Tande AJ; Tommaso CP; Hainy CM; Chu H; Murad MH; Berbari EF; Virk A
    Clin Infect Dis; 2021 Sep; 73(6):e1376-e1379. PubMed ID: 33900384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout.
    Zaqout A; Daghfal J; Alaqad I; Hussein SAN; Aldushain A; Almaslamani MA; Abukhattab M; Omrani AS
    Int J Infect Dis; 2021 Jul; 108():116-118. PubMed ID: 33992763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won.
    Torreggiani M; Blanchi S; Fois A; Fessi H; Piccoli GB
    Kidney Int; 2021 Jun; 99(6):1494-1496. PubMed ID: 33887320
    [No Abstract]   [Full Text] [Related]  

  • 19. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapse of class V lupus nephritis after vaccination with COVID-19 mRNA vaccine.
    Tuschen K; Bräsen JH; Schmitz J; Vischedyk M; Weidemann A
    Kidney Int; 2021 Oct; 100(4):941-944. PubMed ID: 34352310
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.